

The logo features the letters 'TTV' in a bold, red, italicized font, followed by 'BIOPHARM' in a white, italicized font with a registered trademark symbol. The entire logo is set against a black diamond-shaped background.

TTV BIOPHARM®

台灣東洋藥品

WELCOME TO JOIN US

March, 2022

Safe Harbor Statement

This presentation contains certain forward-looking statements.

These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

- 1 pricing and product initiatives of competitors;
- 2 legislative and regulatory developments and economic conditions;
- 3 delay or inability in obtaining regulatory approvals or bringing products to market;
- 4 fluctuations in currency exchange rates and general financial market conditions;
- 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;

- 6 increased government pricing pressures;
- 7 interruptions in production
- 8 loss of or inability to obtain adequate protection for intellectual property rights;
- 9 litigation;
- 10 loss of key executives or other employees; and
- 11 adverse publicity and news coverage.

TTY Biopharm cautions that this foregoing list of factors is not exhaustive. There may also be other risks that management is unable to predict at this time that may cause actual results to differ materially from those in forward-looking statements. **You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. TTY Biopharm undertakes no obligation to update publicly or revise any forward-looking statements.** Any statements regarding earnings growth is not a profit forecast and should not be interpreted to mean that TTY Biopharm's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed published earnings or earnings per share forecasts of TTY Biopharm Company Limited.

Company Overview

Market Deployment

Pipeline Status

Financials & ESG Performance

Summary

Q&A

Structure

**(4105 TT)
TTY Biopharm**

Local Segments

Oncology

Intensive Care

Healthcare

CDMO

Business
Development
Division

Major Investments

EnhanX
(50%)*

(8432 TT)
TSH (56.48%)

(6566 TT)
CY Biotech
(49.05%)

Philippines (87%) Vietnam (100%)
Mexico (100%) Korea (100%)
Turkey (100%)

Equity Method


(4162 TT)
PharmaEngine
(18.01%)

ATB Thailand
(40%)

*Note: TTY will hold 67% according to JV agreement.


Revenue Breakdown

sales breakdown year 2021



■ Oncology ■ Infection ■ Healthcare ■ CDMO ■ BDD ■ others

sales breakdown year 2020



■ Oncology ■ Infection ■ Healthcare ■ CDMO ■ BDD ■ others

Major Products (1)

Oncology (TOT)

Intensive Care (TIT)

Health Care (THT)

Solid Tumor (Cancer)

Anazo
(安納柔膜衣錠)



Epicin
(益彼欣注射液)



Folina
(芙琳亞錠)



Gemis
(健仕注射液)



Irino
(益立諾)



Lipo-Dox
(力得微脂體注射液)



Lonsurf
(朗斯弗膜衣錠)



Oxalip
(歐力普注射劑)



Pexeda Inj.
(派癌休注射劑)



TS-1
(愛斯萬膠囊)



Tynen
(汰能注射劑)



UFUR
(友復膠囊)



Hematology

Asadin
(伸定注射劑)



Ivic
(癌微可膜衣錠)



Leavdo
(瑞伏駭膠囊)



Thado
(賽得膠囊)



Supportive Care

Megest
(麥格斯口服懸液劑)



Otril
(嘔速停靜脈注射劑)



Painkyl
(平舒疼口頰溶片)



Zobonic
(抑骨凍晶靜脈注射劑)



* Listed alphabetically.

Major Products (2)

Oncology (TOT)

Brosym C+S
(博益欣)



Flusine
(弗路欣錠)



Oncology (TOT)

Alginos
(胃逆舒)



Algitab
(艾胃逆服)



Intensive Care (TIT)

Cepiro
(希比洛靜脈乾粉
注射劑)



Lipo-AB
(立博微)



Colimycin
(克痢黴素注射劑)



Maxtam
(抑西每靈注射劑)



Intensive Care

BIO-CAL PLUS
(滋骨咀嚼錠)



Sulfin
(速復利錠)



Health Care (THT)

Cubicin
(救必辛注射劑)



METACIN
(西腹黴素注射劑)



Health Care (THT)

"啟而走"動力式
下肢助行器



"富伯"穿戴式動
力手部復健器



* Listed alphabetically.

Agenda

Company Overview

Market Deployment

Pipeline Status


Financials & ESG Performance

Summary

Q&A




Company Overview

- Branch Office/ Affiliate Company (分/子公司)
- In-Licensing Partner (合作夥伴)
- Out-licensing/ Agent/ CMO (經銷/代理/代工)



Overseas Market Revenue & Profit

Vietnam & Philippines turned into profit since 2018.



Transform of success from Southeast Asia to overseas markets as growth driver.

Company Overview

Market Deployment

Pipeline Status

Financials & ESG Performance

Summary

Q&A

Specialty Development / New drugs, Difficult Generic drugs

Product	Type	Indication	Market Value (USD Mn)	Original Pharma	Patent Expired	Expected to Market
Pegylipo (歐洲)	liposome	Ovarian Cancer	600	JJ	2016	2024
*Lipo-AB		Fungal Infection	440	Gilead (liposome type)	2008	2022
Enx-200		MS Acute	1,700 (similar BBB diseases)			2026
Octreotide	microsphere	Acromegaly	1,630	Novartis	2017	2024

*Lipo-AB BE data results are positive.

Risperidone	microsphere	Mental Disorder	960	JJ (non microsphere)	2020	
Leuprolide		Prostate Cancer	1,240	TAP/ Abott & Takeda	2008	

Liposome & Microspheres as Technology Platform

TTY Development & License-in Products

TTY Development

Product	Type	Indication	Approval expected time
*Arsenic Trioxide	Generic	Acute Promyelocytic Leukemia, APL	USA 2021
TTY_2	Generic	Multiple Myeloma, MM	Taiwan 2022-2023 Thailand 2023-2024 Malaysia 2024-2025
TTY_3	New Dosage Form	Infection caused by Gram-negative bacteria	Taiwan 2026
TTY_4	Generic	CML Blood Cancer	Taiwan 2024
TTY_5	New Unit New Drug	Osteoporosis (Paget's disease of bone)	Taiwan 2022

Approval in October, 2021

*Arsenic Trioxide received FDA approval in October, 2021.

License-in

Product	Indication	Partner	Expected to Market
Trabectedin (Yondelis)	Soft Tissue Sarcoma	Spain Co.	2020.9
Remimazolam	Check Sedation General Anesthesia ICU Sedation	Paion AG	2022
TTY_W	Onychomycosis	Japan Co.	1H/2022
TTY_Y	Chicken Pox Prevention	Japan Co.	2022
TTY_Z	Multiple Myeloma	Taiwan Co.	2024
TTY_X	(cIAI) complicated Intra-Abdominal Infection	Singapore Subsidiary	2024

Signed contract on 2021.3.5

Overseas markets penetration & pipeline development as the Dual Growth Engine.

Development Strategy- Growth Momentum



Agenda

Company Overview

Market Deployment


Pipeline Status

Financials & ESG Performance

Summary

Q&A

Financial Performance (Consolidated)



Year 2021 Financials

NTD in Mn

Item	2021		2020		Variance	YoY
	Amount	%	Amount	%		
Net Sales	4,536	100%	4,221	100%	315	7.5%
Gross Profit	2,767	61%	2,607	62%	601	6.1%
Operating Expenses	(1,626)	36%	(1,650)	39%	(24)	-1.5%
Operating Profit	1,141	25%	957	23%	184	19.2%
Non-Operating Income (Loss)	(53)	-1%	244	6%	(297)	-121%
Income before Tax	1,087	24%	1,202	29%	(115)	-9.6%
Net Income (Consolidated)	823	18%	979	24%	(156)	-15.9%
Net Income (TTY)	832	18%	924	23%	(92)	-10%
EPS (NT)	3.35		3.72		(0.37)	-9.9%
Gross Margin	61.0%		61.7%		-0.7 ppt	
Operating Margin	25.2%		22.6%		2.6 ppts	
Net Margin	18.1%		23.2%		-5.1 ppts	

Solid Balance Sheet / Stable Cash flow


Balance Sheet

NTD Mn	2021	2020
Total Debt	2,123	2,144
Net Debt	(419)	(360)
Net Debt/Equity	-8%	-7%
Current Ratio	156%	188%
Book value/share(NT\$)	20.8	21.9

Cash Flow


NTD Mn	2021	2020
from Operating	1,257	526
from Investing	(169)	147
from Financing	(1,044)	(806)
FX Impact	(45)	(65)
Net Cash Flow	(1)	(198)
Beginning Balance	2,224	2,422
Ending Balance	2,222	2,224

Dividend Payout



* The distribution of 2021 cash dividends is subject to the approval of the shareholders' meeting in 2022.

ESG Focus



Agenda

Company Overview

Market Deployment

Pipeline Status

Financials & ESG Performance

Summary

Q&A

Product Pipeline

- A Generic drug, Arsenic Trioxide, received US FDA approval in October, 2021.
- Lipo-AB (North America) / Pegylipo (Europe) and Octreotide (North America) markets are in progress continuously.
- Continue to expand revenue scale through license-in.
- Self-developed products to expand the scale of revenue.

Dividend Policy

- Maintain cash payout rate above 75%.

2022 Business Outlook

- Revenue of domestic sales is expected to increase 5%-10% annually.
- Strengthen the OEM or distribution business of various vaccines.
- Expected milestone income from global partners.
- Strengthen R&D capabilities and introduce new products through license-in actively.

